PMID: 8609262Mar 1, 1996Paper

Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders

Journal of the American Academy of Dermatology
E C VonderheidM E Kadin

Abstract

The spectrum of primary cutaneous CD30+ lymphoproliferative disease consists of lymphomatoid papulosis (LyP) at one extreme and CD30+ peripheral T-cell lymphoma (Ki-1+ lymphoma) presenting in the skin at the other extreme. Methotrexate has been reported to be effective in LyP, but the experience has been limited to single case reports or small series. The objective was to determine the effectiveness of methotrexate in the treatment of primary cutaneous DC30+ lymphoproliferative disease. We reviewed our 20-year experience with the use of methotrexate in 45 patients with relatively severe LyP, Ki-1+ lymphoma, and interface presentations. During induction of methotrexate therapy patients received maximum doses ranging from 10 to 60 mg/week (median, 20 mg/week). Clinical improvement usually occurred quickly, typically at doses of 15 to 20 mg weekly, and satisfactory long-term control was achieved in 39 patients (87%) with maintainance doses given at 10 to 14-day intervals (range, 7 to 28 days). After methotrexate was discontinued, 10 patients remained free of CD30+ lesions from more than 24 months to more than 227 months (median, more than 127 months). The median total duration of methotrexate therapy for all patients exceeded 39 m...Continue Reading

References

Jul 1, 1979·The British Journal of Dermatology·C Kennedy, K V Sanderson
Oct 1, 1987·Journal of the American Academy of Dermatology·K Thomsen, G L Wantzin
Jul 1, 1988·Journal of the American Academy of Dermatology·H H RoenigkG D Weinstein
Sep 1, 1986·Journal of the American Academy of Dermatology·G S WoodR A Warnke
Jul 11, 1986·JAMA : the Journal of the American Medical Association·G BurgO Braun-Falco
Nov 1, 1984·The British Journal of Dermatology·M A Everett
Jul 1, 1984·The British Journal of Dermatology·G Lange Wantzin, K Thomsen
Aug 1, 1982·The British Journal of Dermatology·R WillemzeE Scheffer

❮ Previous
Next ❯

Citations

Nov 19, 2009·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·C MühlhoffM Megahed
Oct 25, 2003·Journal of the American Academy of Dermatology·Jane S Bergstrom, Christine Jaworsky
May 1, 1997·Journal of the American Academy of Dermatology·M F DemierreH K Koh
May 20, 1998·Dermatologic Clinics·J P Dutz, V C Ho
Mar 17, 2004·The American Journal of Dermatopathology·Wei-Ming Wu, Hsiang-Ju Tsai
May 10, 2011·American Journal of Clinical Oncology·Edward PerryImad A Tabbara
Nov 24, 1999·Journal of the European Academy of Dermatology and Venereology : JEADV·T GambichlerS Menzel
Sep 17, 2011·Future Oncology·Eric Tse, Yok-Lam Kwong
Aug 21, 2001·The Journal of Dermatology·N YazawaK Jimbow
May 7, 2002·The Journal of Dermatology·Toshiyuki YamamotoKiyoshi Nishioka
Nov 27, 2015·American Journal of Hematology·Ryan A Wilcox
Nov 1, 2015·Journal of the American Academy of Dermatology·Iris WieserMadeleine Duvic
Apr 29, 2009·The Australasian Journal of Dermatology·Michelle RodriguesPeter Foley
Oct 13, 2011·American Journal of Hematology·Ryan A Wilcox
Mar 31, 2012·International Journal of Dermatology·Irene FuertesTeresa Estrach Estrach
Feb 9, 2012·The Australasian Journal of Dermatology·Sarah ShenChristopher J McCormack
Nov 11, 2011·The Australasian Journal of Dermatology·Leona YipDavid Orchard
Oct 13, 2009·Journal of Cutaneous Pathology·Navid EzraScott W Binder
Jul 29, 2004·Journal of the American Academy of Dermatology·Joel M GelfandJacqueline M Junkins-Hopkins
Dec 1, 1996·Baillière's Clinical Haematology·R Russell-Jones, M F Spittle
Jan 13, 2001·Dermatologic Clinics·N G Silvis
Jan 9, 2004·Hematology/oncology Clinics of North America·Rein Willemze, Chris J L M Meijer
Oct 5, 2015·Dermatologic Clinics·Gary S Wood, Jianqiang Wu
Oct 5, 2015·Dermatologic Clinics·Lauren C Hughey
Jul 20, 2010·International Journal of Dermatology·Lucía Carnero GonzálezRicardo Soloeta Arechavala
Jul 22, 2014·American Journal of Hematology·Ryan A Wilcox
Nov 18, 2008·Expert Opinion on Investigational Drugs·Lauren C Pinter-Brown
May 20, 2015·Journal of the American Academy of Dermatology·Kate M NewlandH Miles Prince
Apr 22, 2016·Current Hematologic Malignancy Reports·Meenal KheterpalSteven M Horwitz
May 28, 2016·Pediatric Blood & Cancer·Francesco CeppiOussama Abla
Jun 21, 2005·Journal of the American Academy of Dermatology·Julie C SchultzSam T Hwang
Oct 10, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Reed E Drews
Apr 6, 2017·Indian Journal of Pediatrics·Nirav ThackerBrijesh Arora
Jul 10, 2004·Journal of the American Academy of Dermatology·James M ShehanIftikhar Ahmed
Feb 12, 2017·Behavioural and Cognitive Psychotherapy·Marie Claire Van HoutMichael Bergin
Jun 11, 2019·The Journal of Dermatological Treatment·Neil PanjwaniSusan M Hiniker

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.